title: [Testosterone replacement in hypogonadotropic hypogonadal young male improves insulin sensitivity].
abstract: OBJECTIVE
  To evaluate the effect of testosterone replacement therapy in patients with hypogonadotrophic hypogonadism (HH) on insulin sensitivity and high sensitivity C reactive protein (hsCRP).
  
  
  METHODS
  21 males with HH, aged 15 - 30, and 18 age, and BMI-matched healthy males underwent detection of homeostasis model assessment insulin resistance index (HOMA-IR). Second, the values of weight, abdominal circumstance, grips strength, body composition, total testosterone (TT), fast blood glucose and insulin, serum lipid profile, and hsCRP were compared before and after 9-month testosterone replacement therapy in the HH patient group.
  
  
  RESULTS
  (1) Before treatment the TT level of the HH patients WAS (0.9 +/- 0.6) nmol/L, significantly lower than that of the healthy control group (18.8 +/- 3.2) nmol/L. The fast insulin level of the HH patients was (16.0 +/- 9.8) mIU/L, significantly higher than that of the control group [(8.4 +/- 3.3) mIU/L, P = 0.018]. The HOMA-IR of the HH patient was 3.7 +/- 2.4, not significantly different from that of the control group (1.8 +/- 0.7, P = 0.021). (2) After testosterone therapy, the fast insulin level of the HH patients decreased from (16.0 +/- 9.8) mIU/L to (12.1 +/- 7.4) mIU/L (P = 0.03); the HOMA-IR decreased from (3.7 +/- 2.4) to (2.7 +/- 1.7) (P = 0.045); and the total cholesterol, LDL-c, HDL-c, and Triglyceride all decreased, but not significantly (all P > 0.05). The hsCRP decreased from (1.49 +/- 1.18) mg/L to (0.70 +/- 0.56) mg/L (P = 0.025).
  
  
  CONCLUSIONS
  Short period of testosterone replacement therapy in young HH male patients significantly improves the insulin sensitivity and decreases the risk of cardiovascular disease.
authors.affiliation: Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China.
authors.forename: Jiang-feng
authors.initials: JF
authors.lastname: Mao
authors.forename: Xue-yan
authors.initials: XY
authors.lastname: Wu
authors.forename: Nai-shi
authors.initials: NS
authors.lastname: Li
authors.forename: Shuang-yu
authors.initials: SY
authors.lastname: Lu
authors.forename: Zi-meng
authors.initials: ZM
authors.lastname: Jing
authors.forename: Yi-fan
authors.initials: YF
authors.lastname: Shi
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy* / Q000378:metabolism; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D008297:Male; D011446:Prospective Studies; D013739:Testosterone / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007328:Insulin; D013739:Testosterone; D002097:C-Reactive Protein